Related Experiment Video

Updated: Jul 7, 2026

Retinal Pathophysiological Evaluation in a Rat Model
09:11

Retinal Pathophysiological Evaluation in a Rat Model

Published on: May 6, 2022

Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication

Sho-ichi Yamagishi1, Kazuo Nakamura, Takanori Matsui

  • 1Division of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan. shoichi@med.kurume-u.ac.jp

Current Pharmaceutical Design
|February 22, 2008
PubMed

Insights

Advanced glycation end products (AGEs) and their receptor (RAGE) contribute to diabetic vascular complications. Targeting the AGE-RAGE pathway offers a promising therapeutic strategy for managing diabetes-related vascular damage.

Area of Science:

  • Endocrinology
  • Vascular Biology
  • Diabetology

Background:

  • Diabetic vascular complications, including blindness and renal failure, are major causes of morbidity and mortality.
  • Hyperglycemia-induced metabolic and hemodynamic changes contribute to these complications.
  • The formation and accumulation of advanced glycation end products (AGEs) are strongly linked to 'hyperglycemic memory' in diabetes.

Purpose of the Study:

  • To review the role of the AGE-RAGE axis in diabetic vascular complications.
  • To discuss potential therapeutic agents targeting RAGE expression or its downstream signaling pathways.

Main Methods:

  • Literature review focusing on the pathogenesis of diabetic vascular complications.
  • Analysis of studies investigating the AGE-RAGE interaction and its cellular effects.
  • Evaluation of therapeutic strategies aimed at inhibiting RAGE signaling.

Main Results:

  • The AGE-RAGE axis plays a critical role in the pathogenesis of diabetic micro- and macroangiopathy.
  • AGE-RAGE engagement triggers oxidative stress and inflammatory responses.
  • Inhibition of RAGE expression or downstream signaling shows therapeutic potential.

Conclusions:

  • The AGE-RAGE axis is a key mediator of diabetic vascular complications.
  • Down-regulating RAGE or blocking its signaling pathways represents a promising therapeutic target.
  • Further research into AGE-RAGE inhibitors could lead to novel treatments for diabetic vascular disease.

Related Concept Videos

Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...